192 related articles for article (PubMed ID: 31420414)
1. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Lorusso D; Hilpert F; González Martin A; Rau J; Ottevanger P; Greimel E; Lück HJ; Selle F; Colombo N; Kroep JR; Mirza MR; Berger R; Pardo B; Grischke EM; Berton-Rigaud D; Martinez-Garcia J; Vergote I; Redondo A; Cardona A; Bastière-Truchot L; du Bois A; Kurzeder C;
Int J Gynecol Cancer; 2019 Sep; 29(7):1141-1147. PubMed ID: 31420414
[TBL] [Abstract][Full Text] [Related]
2. Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).
Kurzeder C; Bover I; Marmé F; Rau J; Pautier P; Colombo N; Lorusso D; Ottevanger P; Bjurberg M; Marth C; Barretina-Ginesta P; Vergote I; Floquet A; Del Campo JM; Mahner S; Bastière-Truchot L; Martin N; Oestergaard MZ; Kiermaier A; Schade-Brittinger C; Polleis S; du Bois A; Gonzalez-Martin A
J Clin Oncol; 2016 Jul; 34(21):2516-25. PubMed ID: 27269942
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
González-Martín A; Pautier P; Mahner S; Rau J; Colombo N; Ottevanger P; Del Campo JM; Selle F; du Bois A; Gadducci A; García Y; Berton-Rigaud D; Marmé F; Ortega E; Martin N; Bastiere-Truchot L; Kiermaier A; Kurzeder C
Int J Gynecol Cancer; 2016 Jun; 26(5):898-905. PubMed ID: 27206218
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Makhija S; Amler LC; Glenn D; Ueland FR; Gold MA; Dizon DS; Paton V; Lin CY; Januario T; Ng K; Strauss A; Kelsey S; Sliwkowski MX; Matulonis U
J Clin Oncol; 2010 Mar; 28(7):1215-23. PubMed ID: 19901115
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Monk BJ; Colombo N; Oza AM; Fujiwara K; Birrer MJ; Randall L; Poddubskaya EV; Scambia G; Shparyk YV; Lim MC; Bhoola SM; Sohn J; Yonemori K; Stewart RA; Zhang X; Perkins Smith J; Linn C; Ledermann JA
Lancet Oncol; 2021 Sep; 22(9):1275-1289. PubMed ID: 34363762
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Schneeweiss A; Park-Simon TW; Albanell J; Lassen U; Cortés J; Dieras V; May M; Schindler C; Marmé F; Cejalvo JM; Martinez-Garcia M; Gonzalez I; Lopez-Martin J; Welt A; Levy C; Joly F; Michielin F; Jacob W; Adessi C; Moisan A; Meneses-Lorente G; Racek T; James I; Ceppi M; Hasmann M; Weisser M; Cervantes A
Invest New Drugs; 2018 Oct; 36(5):848-859. PubMed ID: 29349598
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Haldar K; Gaitskell K; Bryant A; Nicum S; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2011 Oct; (10):CD007927. PubMed ID: 21975775
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer.
Kaye SB; Poole CJ; Dańska-Bidzińska A; Gianni L; Del Conte G; Gorbunova V; Novikova E; Strauss A; Moczko M; McNally VA; Ross G; Vergote I
Ann Oncol; 2013 Jan; 24(1):145-52. PubMed ID: 23002282
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
Richardson DL; Sill MW; Coleman RL; Sood AK; Pearl ML; Kehoe SM; Carney ME; Hanjani P; Van Le L; Zhou XC; Alvarez Secord A; Gray HJ; Landrum LM; Lankes HA; Hu W; Aghajanian C
JAMA Oncol; 2018 Feb; 4(2):196-202. PubMed ID: 29242937
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
13. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
Nagumo Y; Faratian D; Mullen P; Harrison DJ; Hasmann M; Langdon SP
Mol Cancer Res; 2009 Sep; 7(9):1563-71. PubMed ID: 19737968
[TBL] [Abstract][Full Text] [Related]
14. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Edwards SJ; Barton S; Thurgar E; Trevor N
Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Chekerov R; Hilpert F; Mahner S; El-Balat A; Harter P; De Gregorio N; Fridrich C; Markmann S; Potenberg J; Lorenz R; Oskay-Oezcelik G; Schmidt M; Krabisch P; Lueck HJ; Richter R; Braicu EI; du Bois A; Sehouli J; ;
Lancet Oncol; 2018 Sep; 19(9):1247-1258. PubMed ID: 30100379
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
18. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
[TBL] [Abstract][Full Text] [Related]
19. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
20. Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Harter P; Pautier P; Van Nieuwenhuysen E; Reuss A; Redondo A; Lindemann K; Kurzeder C; Petru E; Heitz F; Sehouli J; Degregorio N; Wimberger P; Burges A; Cron N; Ledermann J; Lorusso D; Paoletti X; Marme F
Int J Gynecol Cancer; 2020 Dec; 30(12):1997-2001. PubMed ID: 32606097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
